Novartis secures FDA accelerated approval for Vanrafia for IgAN
Vanrafia is an oral, once-daily, non-steroidal treatment that complements renin-angiotensin system (RAS) inhibitor, with or without a sodium-glucose co-transporter-2 (SGLT2) inhibitor
Pfizer secures expanded EC authorisation for Abrysvo vaccine
Cellares secures FDA AMT Designation for Cell Shuttle technology
Alnylam’s Qfitlia receives FDA nod for haemophilia A and B treatment
Novartis gets FDA approval for Pluvicto to treat advanced prostate cancer
AstraZeneca gets FDA nod for Imfinzi regimen to treat MIBC
Analysis
View More
Risks
View MoreSocietal polarisation and its impact on the pharmaceutical industry
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry